Literature DB >> 18607744

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).

I V Damulin1, N N Koberskaya, E A Mkhitaryan.   

Abstract

The efficacy of treatment with cerebrolysin was studied in 40 patients with cerebral vascular insufficiency. Cerebrolysin (20 daily i.v. infusions of 10 ml in 200 ml of physiological saline) was found to be an effective means of treating this group of patients. Courses of cerebrolysin treatment decreased the severity of memory and attention impairments, improving the overall cognitive status of the patients. Clinical observations and neuropsychological testing were supported by electrophysiological results, in terms of the P300 cognitive evoked potential. The effects of treatment at the doses used here were delayed and were seen three months after completion of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607744     DOI: 10.1007/s11055-008-9014-5

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  18 in total

1.  Role of frontal cortex in memory for duration: an event-related potential study in humans.

Authors:  V Monfort; V Pouthas; R Ragot
Journal:  Neurosci Lett       Date:  2000-06-02       Impact factor: 3.046

2.  Event-related potentials in patients with multiple lacunar infarcts.

Authors:  H Tachibana; K Toda; M Sugita
Journal:  Gerontology       Date:  1992       Impact factor: 5.140

3.  [Clinical experience with Cerebrolysin in severe lesions of the cerebral cortex].

Authors:  F Jelasić
Journal:  ZFA (Stuttgart)       Date:  1976-12-20

Review 4.  [The application of cerebrolysine in ischemic stroke].

Authors:  B S Vilenskiĭ; G M Semenova; E A Shirokov
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  1999

5.  [Experience with using high doses of cerebrolysin in vascular dementia].

Authors:  N N Iakhno; I V Damulin; V V Zakharov; O S Levin; M N Elkin
Journal:  Ter Arkh       Date:  1996       Impact factor: 0.467

6.  [Classification of vascular lesions of the brain and spinal cord].

Authors:  E V Shmidt
Journal:  Zh Nevropatol Psikhiatr Im S S Korsakova       Date:  1985

Review 7.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

Review 8.  The p300: where in the brain is it produced and what does it tell us?

Authors:  David E J Linden
Journal:  Neuroscientist       Date:  2005-12       Impact factor: 7.519

9.  Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.

Authors:  E Rüther; R Ritter; M Apecechea; S Freytag; R Gmeinbauer; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

10.  Cerebral blood flow and event-related potential in patients with multiple cerebral infarcts.

Authors:  H Tachibana; K Toda; N Yokota; M Sugita; K Konishi
Journal:  Int J Neurosci       Date:  1991-09       Impact factor: 2.292

View more
  4 in total

Review 1.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 2.  Pharmacological interventions for unilateral spatial neglect after stroke.

Authors:  Gustavo José Luvizutto; Rodrigo Bazan; Gabriel Pereira Braga; Luiz Antônio de Lima Resende; Silméia Garcia Z Bazan; Regina El Dib
Journal:  Cochrane Database Syst Rev       Date:  2015-11-06

3.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11

4.  Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential.

Authors:  Qiang Liu; Xiu-Juan Wang; Zhe-Cheng Zhang; Rong Xue; Ping Li; Bo Li
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.